+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 65 Pages
  • September 2023
  • GlobalData
  • ID: 1315558
CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CSL Ltd (CSL) discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, neurological disorders, respiratory disease, and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.

CSL Ltd Key Recent Developments

  • Aug 28, 2023: CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
  • Aug 21, 2023: Prime Minister Anthony Albanese Opens CSL’s New Global Headquarters and Centre for Research & Development
  • Aug 17, 2023: CSL Appoints Jeffrey Ball as First Chief Sustainability Officer
  • Jun 14, 2023: CSL : Market Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • CSL Ltd - Key Facts
  • CSL Ltd - Key Employees
  • CSL Ltd - Key Employee Biographies
  • CSL Ltd - Major Products and Services
  • CSL Ltd - History
  • CSL Ltd - Company Statement
  • CSL Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • CSL Ltd - Business Description
  • Business Segment: CSL Behring
  • Overview
  • Performance
  • Business Segment: CSL Seqirus
  • Overview
  • Performance
  • Business Segment: CSL Vifor
  • Performance
  • Performance
  • Geographical Segment: Australia
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: Switzerland
  • Performance
  • Geographical Segment: UK
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • CSL Ltd - Corporate Strategy
  • CSL Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • CSL Ltd - Strengths
  • CSL Ltd - Weaknesses
  • CSL Ltd - Opportunities
  • CSL Ltd - Threats
  • CSL Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • CSL Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 28, 2023: CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
  • Aug 21, 2023: Prime Minister Anthony Albanese Opens CSL’s New Global Headquarters and Centre for Research & Development
  • Aug 17, 2023: CSL Appoints Jeffrey Ball as First Chief Sustainability Officer
  • Jun 14, 2023: CSL : Market Update
  • May 22, 2023: CSL Seqirus’ $800m+ innovative vaccine and antivenom manufacturing facility in Australia reaches major construction milestone
  • Mar 28, 2023: CSL opens new, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
  • Feb 21, 2023: CSL : Portfolio update
  • Dec 13, 2022: CSL closes mRNA vaccine deal with Arcturus
  • Dec 12, 2022: CSL Announces Next CEO & Managing Director
  • Dec 07, 2022: CSL opens new Australian Plasma Fractionation Facility
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • CSL Ltd, Key Facts
  • CSL Ltd, Key Employees
  • CSL Ltd, Key Employee Biographies
  • CSL Ltd, Major Products and Services
  • CSL Ltd, History
  • CSL Ltd, Other Locations
  • CSL Ltd, Subsidiaries
  • CSL Ltd, Key Competitors
  • CSL Ltd, Ratios based on current share price
  • CSL Ltd, Annual Ratios
  • CSL Ltd, Interim Ratios
  • CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • CSL Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • CSL Ltd, Performance Chart (2019 - 2023)
  • CSL Ltd, Ratio Charts
  • CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Gilead Sciences Inc
  • Bayer AG
  • Alexion Pharmaceuticals Inc
  • GSK plc
  • AbbVie Inc
  • Regeneron Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Grifols SA
  • UCB SA
  • Merck KGaA & Co Werk Spittal
  • Biogen Inc
  • Bausch Health Companies Inc
  • Amgen Inc
  • Vertex Pharmaceuticals Inc
  • Bioverativ Inc
  • Novo Nordisk AS
  • Eli Lilly and Company Ltd
  • AstraZeneca Plc
  • Allergan Ltd
  • Gilead Sciences Inc
  • Bioverativ Inc
  • UCB SA
  • Merck KGaA & Co Werk Spittal
  • Biogen Inc
  • Bausch Health Companies Inc
  • Amgen Inc
  • Novo Nordisk AS
  • Eli Lilly and Company Ltd
  • AstraZeneca Plc
  • Alexion Pharmaceuticals Inc
  • Allergan Ltd
  • Regeneron Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Grifols SA
  • Bayer Aktiengesellschaft Leverkusen
  • Vertex Pharmaceuticals Inc
  • GSK plc
  • AbbVie Inc